198 related articles for article (PubMed ID: 34157632)
21. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
[TBL] [Abstract][Full Text] [Related]
22. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study.
Deng Y; Wu J; Jia Q
Med Sci Monit; 2017 Mar; 23():1254-1260. PubMed ID: 28285317
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR; Mason NA; Valaoras TG
Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
[TBL] [Abstract][Full Text] [Related]
25. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
26. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease).
Mehmood T; Auerbach M; Earley CJ; Allen RP
Sleep Med; 2014 Dec; 15(12):1473-6. PubMed ID: 25441748
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women.
Shim JY; Kim MY; Kim YJ; Lee Y; Lee JJ; Jun JK; Shin JC; Cho YK; Lee KY; Kim A; Song TB
BMC Pregnancy Childbirth; 2018 Aug; 18(1):349. PubMed ID: 30153811
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.
Grote L; Leissner L; Hedner J; Ulfberg J
Mov Disord; 2009 Jul; 24(10):1445-52. PubMed ID: 19489063
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.
Trenkwalder C; Hundemer HP; Lledo A; Swieca J; Polo O; Wetter TC; Ferini-Strambi L; de Groen H; Quail D; Brandenburg U;
Neurology; 2004 Apr; 62(8):1391-7. PubMed ID: 15111679
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
31. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J;
J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921
[TBL] [Abstract][Full Text] [Related]
32. A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China.
Jin J; Ran Z; Noseda E; Roubert B; Marty M; Mezzacasa A; Göring UM
Front Med; 2024 Feb; 18(1):98-108. PubMed ID: 37897561
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
35. Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents.
Ozsahin H; Schaeppi M; Bernimoulin M; Allard M; Guidard C; van den Ouweland F
Pediatr Blood Cancer; 2020 Oct; 67(10):e28614. PubMed ID: 32729200
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
Naqash A; Ara R; Bader GN
BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
40. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]